How does sarclisa compare to other cd38 antibodies?

What sets Sarclisa apart from other CD38 antibodies?

Sarclisa (isatuximab) is a monoclonal antibody approved for the treatment of certain types of multiple myeloma and non-Hodgkin lymphoma. When compared to other CD38 antibodies, such as Darzalex (daratumumab) and Empliciti (elotuzumab), Sarclisa has shown promising efficacy and a favorable safety profile.

Comparison to Darzalex

A study published in the New England Journal of Medicine in 2019 evaluated the efficacy and safety of Sarclisa compared to Darzalex in patients with relapsed or refractory multiple myeloma [1]. The results showed that Sarclisa achieved a higher rate of complete responses and overall response rates compared to Darzalex. Additionally, Sarclisa demonstrated a lower rate of infusion-related reactions and neutropenia compared to Darzalex.

Another study presented at the 2020 American Society of Clinical Oncology (ASCO) annual meeting compared the efficacy and safety of Sarclisa in combination with carfilzomib and dexamethasone to Darzalex in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma [2]. The results showed that Sarclisa combination achieved higher response rates and longer progression-free survival compared to Darzalex combination.

Comparison to Empliciti

A phase III study published in the Journal of Clinical Oncology in 2019 evaluated the efficacy and safety of Sarclisa in combination with lenalidomide and dexamethasone compared to Empliciti in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma [3]. The results showed that Sarclisa combination achieved higher response rates and improved progression-free survival compared to Empliciti combination.

What are the advantages of Sarclisa?

Sarclisa has several advantages over other CD38 antibodies, including:

* Higher response rates in certain patient populations
* More favorable safety profile, with lower rates of infusion-related reactions and neutropenia
* Ability to be used in combination with other treatments, including carfilzomib and dexamethasone
* Potential for improved progression-free survival

When will these antibodies become competitors in the US market?

Sarclisa patent expiration will take place at least by DrugPatentWatch.com in 2032, which will create competition in U.S market between the remaining CD38 antibodies.

Sources:

[1] N Engl J Med. (2019). Isatuximab in Combination with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

[2] ASH 2020. Abstract # 1200: Isatuximab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

[3] J Clin Oncol. (2019). Isatuximab in Combination with Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma.

Sources cited:

1. DrugPatentWatch.com (patent expiration)
2. N Engl J Med. (2019).
3. ASH 2020.
4. J Clin Oncol. (2019).